Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application.

Please amend claims 25, 26, and 28.

- 1. (withdrawn) A therapeutic agent for inhibiting vascularization comprising as the effective ingredient, a substance that inhibits the action due to CXCR4.
- 2. (withdrawn) A therapeutic agent for a solid cancer comprising as the effective ingredient, a substance that inhibits the action due to CXCR4.
- 3. (withdrawn) A therapeutic agent for a disease pathologically caused by neovascularization comprising as the effective ingredient, a substance that inhibits the action due to CXCR4.
- 4. (withdrawn) A therapeutic agent for repairing a tissue comprising as the effective ingredient, a substance that inhibits the action due to CXCR4.
- 5. (withdrawn) The therapeutic agent according to claim 1, wherein the substance inhibits the binding between SDF-1 and CXCR4.
- 6. (withdrawn) The therapeutic agent according to claim 1, wherein the substance inhibits signaling from CXCR4 to nuclei.
- 7. (withdrawn) The therapeutic agent according to claim 1, wherein the substance inhibits the expression of CXCR4.
- 8. (withdrawn) The therapeutic agent according to claim 1, wherein the substance inhibits the expression of SDF-1.
 - 9. (withdrawn) The therapeutic agent according to claim 5, wherein the substance inhibits SDF-1.
- 10. (withdrawn) The therapeutic agent according to claim 5, wherein the substance inhibits CXCR4.
- 11. (withdrawn) The therapeutic agent according to claim 9, wherein the substance inhibits CXCR4 in antagonistic competition with SDF-1.

- 12. (withdrawn) The therapeutic agent according to claim 9, wherein the substance inhibits SDF-1 from binding to CXCR4 by binding to SDF-1.
- 13. (withdrawn) The therapeutic agent according to claim 11, wherein the substance is one selected from the group consisting of a SDF-1-like protein, a fused protein of the foregoing protein with another peptide or polypeptide, a partial peptide of SDF-1, and a low molecular weight compound having a structure similar to a binding site of SDF-1.
- 14. (withdrawn) The therapeutic agent according to claim 12, wherein the substance is one selected from the group consisting of an anti-SDF-1 antibody, a fragment of said antibody possessing the activity of the anti-SDF-1 antibody, a fused protein possessing binding activity to SDF-1, a substance that induces a structural change in SDF-1, and a low molecular weight compound capable of binding to the CXCR4-binding site of SDF-1.
- 15. (withdrawn) The therapeutic agent according to claim 10, wherein the substance inhibits CXCR4 in antagonistic competition with CXCR4 for binding to SDF-1.
- 16. (withdrawn) The therapeutic agent according to claim 10, wherein the substance inhibits SDF-1 from binding to CXCR4 by binding to CXCR4.
- 17. (withdrawn) The therapeutic agent according to claim 15, wherein the substance is one selected from the group consisting of a soluble CXCR4 that antagonizes CXCR4 in the inhibition, a protein having a CXCR4-like structure, a fused protein of the foregoing protein with another peptide or polypeptide, a partial peptide of CXCR4, and a low molecular weight compound having a structure similar to a binding site of SDF-1.
- 18. (withdrawn) The therapeutic agent according to claim 16, wherein the substance is one selected from the group consisting of an anti-CXCR4 antibody, a fragment of said antibody possessing the activity of anti-CXCR4 antibody, a fused protein possessing a binding activity to CXCR4, a substance that induces a structural change in SDF-1, and a low molecular weight compound capable of binding to the SDF-1-binding site of CXCR4.
- 19. (withdrawn) The therapeutic agent according to claim 6, wherein the substance is an inhibitor of a signaling system located downstream of a G protein-coupled protein and is one selected from the group consisting of a MAPK cascade inhibitor, a phospholipase C (PLC) inhibitor, and a PI3 kinase inhibitor.

- 20. (withdrawn) The therapeutic agent according to claim 7, wherein the substance is a substance that causes apparent disappearance of CXCR4 from cells by acting on a cell membrane to vary fluidity thereof and to cause disappearance of CXCR4 from the cell membrane.
- 21. (withdrawn) The therapeutic agent according to claim 7, wherein the substance is a substance that inhibits the expression of CXCR4 and is one selected from the group consisting of an antigene, an antisense polynucleotide, and an antisense RNA expressed by an antisense vector, a ribosome, and an inhibitor against the expression control site of CXCR4.
- 22. (withdrawn) The therapeutic agent according to claim 8, wherein the substance is an antisense polynucleotide capable of inhibiting the expression of SDF-1.
- 23. (withdrawn) The therapeutic agent according to claim 8, wherein the substance inhibits the expression control site of SDF-1.
 - 24. (cancelled)
- 25. (currently amended) A method for treating a solid tumor comprising administering a substance that inhibits human CXCR4 to a human subject expressing CXCR4 in need thereof, wherein the substance inhibits the binding between the human ligand SDF-1 and the human receptor CXCR4, wherein the substance is selected from the group consisting of:
- i) an anti-human CXCR4 antibody, or a fragment thereof possessing binding activity to CXCR4; and
 - ii) an anti-human SDF-1 antibody, or a fragment thereof possessing binding activity to SDF-1.
- 26. (currently amended) A method for treating a disease pathologically caused by neovascularization comprising administering a substance that inhibits human CXCR4 to a human subject expressing CXCR4 in need thereof, wherein the substance inhibits binding between the human ligand SDF-1 and the human receptor CXCR4, wherein the substance is selected from the group consisting of:
- i) an anti-human CXCR4 antibody, or a fragment thereof possessing binding activity to CXCR4; and
 - ii) an anti-human SDF-1 antibody, or a fragment thereof possessing binding activity to SDF-1.
- 27. (withdrawn) A method for repairing a tissue comprising administering a substance that inhibits the action due to CXCR4 to a mammal in need thereof.

- 28. (currently amended) A method for suppressing vascularization comprising administering a substance that inhibits human CXCR4 to a human subject expressing CXCR4 in need thereof, wherein the substance inhibits the binding between the human ligand SDF-1 and the human receptor CXCR4, wherein the substance is selected from the group consisting of:
- i) an anti-human CXCR4 antibody, or a fragment thereof possessing binding activity to CXCR4; and
 - ii) an anti-human SDF-1 antibody, or a fragment thereof possessing binding activity to SDF-1.
- 29. (withdrawn) A method for suppressing vascularization comprising administering a substance that inhibits the action of CXCR4 in a mammal in need thereof, wherein the substance inhibits signaling from CXCR4 to nuclei.
- 30. (withdrawn) A method for suppressing vascularization comprising administering a substance that inhibits the action of CXCR4 in a mammal in need thereof, wherein the substance inhibits the expression of SDF-1.